公司概覽
業務類別 Diagnostics & Research
業務概覽 Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ inthe office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
公司地址 One IDEXX Drive, Westbrook, ME, USA, 04092
電話號碼 +1 207 556-0300
傳真號碼 +1 207 556-4346
公司網頁 https://www.idexx.com
員工數量 11000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Michael G. Erickson, PhD Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine -- 13/01/2026
Mr. Andrew J. Emerson Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer 美元 531.15K 27/03/2026
Mr. George J. Fennell Executive Vice President, Global CAG Commercial -- 27/03/2026
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 美元 1.15M 13/01/2026
Dr. Martin Alexander Smith, PhD Executive Vice President, Global Operations and Research and Development 美元 594.05K 27/03/2026
Ms. Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary -- 27/03/2026
Mr. Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology 美元 594.05K 27/03/2026
Mr. Michael Schreck Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience -- 27/03/2026
Mr. Michael P. Johnson Senior Vice President and Chief Human Resources Officer -- 27/03/2026
 
董事會成員
董事會 職務 更新日期
Mr. Bruce L. Claflin Independent Director 27/03/2026
Mr. Daniel M. Junius Independent Director 27/03/2026
Ms. M. Anne Szostak Independent Director 13/02/2026
Mr. Lawrence D. Kingsley Non-Executive Chairman of the Board 27/03/2026
Dr. Sophie V. Vandebroek, PhD Independent Director 27/03/2026
Mr. Stuart M. Essig, PhD Independent Director 27/03/2026
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 13/01/2026
Mr. Sam A. Samad Independent Director 27/03/2026
Mr. Joseph L. Hooley Lead Independent Director 27/03/2026
Ms. Karen A. Peacock Independent Director 27/03/2026
Ms. Irene Chang Britt Independent Director 27/03/2026
 
所屬ETF (更新日期: 02/05/2026 04:29)
代號 名稱 佔比% 持有日期
EMOTFirst Trust S&P 500 Economic Moat ETF0.0001%29/04/2026
ONEOStt Strt® SPDR® Russell 1000 Momt FocETF0.0001%29/04/2026
ESLVEventide Large Cap Value ETF0.0001%29/04/2026
QRMIGlobal X NASDAQ 100® Risk Mngd Inc ETF0.0001%29/04/2026
BRESBurney U.S. Equity Select ETF0.0001%29/04/2026
QSIXPacer Metarus Nasdaq 100 Div Mltpl600ETF0.0001%29/04/2026
XRMIGlobal X S&P 500® Risk Managed Inc ETF0.0001%29/04/2026
PHDGInvesco S&P 500® Downside Hedged ETF0.0001%29/04/2026
MNZLManzil Russell Halal USA Broad MarketETF0.0001%29/04/2026
SMAPAmplify Small-Mid Cap Equity ETF0.0001%29/04/2026
AAUAAlpha Architect US Equity 3 ETF0.0001%10/04/2026
TOPCiShares S&P 500 3% Capped ETF0.0001%29/04/2026
GEWCambria Global EW ETF0.00005%29/04/2026
AVOSAvos Global Equities ETF0.00004%29/04/2026
MPLYMonopoly ETF0.00004%29/04/2026
GOFGuggenheim Strategic Opp Fund0.00003%30/11/2025
QRFTQRAFT AI-Enhanced US Large Cap ETF0.00003%29/04/2026
FLAGGlobal X S&P 500 U.S. Mkt Ldr TOP 50 ETF0.00003%29/04/2026
NTSDWisdomTree Efficient U.S. Pls Intl Eq Fd0.00003%29/04/2026
QCLRGlobal X NASDAQ 100® Collar 95-110 ETF0.00002%29/04/2026
  1    2    3    4    5    6    7    8    9    10    11    12    13    14   15    16    17    18    19  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.